eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is currently undergoing a Phase 2b clinical study for patients diagnosed with metastatic non-small cell lung cancer. Furthermore, eFFECTOR is progressing with Zotatifin, another small-molecule therapeutic designed to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 2 clinical trials, exploring its efficacy in treating different solid tumors. A strategic alliance with Pfizer Inc. supports eFFECTOR's work on developing additional eIF4E inhibitors. Founded in 2012, eFFECTOR Therapeutics, Inc. maintains its operational base in Solana Beach, California.